DRG Epidemiology's coverage of type 2 diabetes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of type 2 diabetes for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. DRG Epidemiology's type 2 diabetes forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of type 2 diabetes?
  • Of all people with type 2 diabetes, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with type 2 diabetes, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of type 2 diabetes over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following type 2 diabetes subpopulations:

  • CVD diagnosed prevalent cases by drug-treatment status
  • Glycemic control by drug-treated status
  • Glycemic control by diagnosis status
  • Total prevalent cases by body mass index status
  • Total prevalent cases by diagnosis status
  • Total prevalent cases by renal impairment status

Note: coverage may vary by country and region. Source: Decision Resources Group

Table of contents

  • Type 2 Diabetes - Epidemiology - Mature Markets Data
    • Introduction
      • Prevalence of Type 2 Diabetes per 1,000 Among People Aged 20+ in 2018 and 2038
      • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Type 2 Diabetes over the Next 20 Years
      • Analysis of the Prevalent Cases of Type 2 Diabetes in 2018 by Diagnosed and Drug-Treated Status
      • Analysis of the Prevalent Cases of Type 2 Diabetes in 2018 by Weight Class
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases of T2D
      • Diagnosed Prevalent Cases of T2D
      • Drug-Treated Cases of T2D
      • Total Prevalent Cases of T2D by BMI Status
      • Total Prevalent Cases of T2D by Renal Impairment Status.
      • T2D by Glycemic Control
      • History of CVD
      • Total Prevalent Cases of IGT
      • Lifetime DALYs Gained
      • Total Incident Cases
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of T2D
        • Studies Excluded from the Analysis of T2D
      • Risk/Protective Factors
        • Risk/Protective Factors for T2D
      • Bibliography

    Author(s): Joseph Granato, M.P.H.; Nicole Zhang, M.P.H.

    Joseph Granato, M.P.H., is a senior epidemiologist at DRG, part of Clarivate. Before joining DRG, he worked with the Monroe County Health Department on the surveillance of reportable diseases, including dengue fever. He received his M.P.H. from Des Moines University, where he worked on several population health projects, including tick-borne diseases. He also holds a B.S. in animal science from the University of Tennessee.

    Nicole Zhang, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she worked as a research analyst at Massachusetts General Hospital, where she independently managed data from a food information survey conducted in Chelsea, Massachusetts. She has also worked for the Massachusetts Department of Public Health, conducting secondary research in the field of gestational diabetes. She holds an M.P.H. from Tufts Medical School, where she specialized in epidemiology and biostatistics. She also holds a B.A. in chemistry and statistics from Mount Holyoke College.


    Related Reports

    Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

    View Details

    Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

    The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in th...

    View Details

    Type 2 Diabetes - Epidemiology - Extrapolated Worldwide Coverage

    DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient...

    View Details

    Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) Dashboard

    Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of...

    View Details